methyl ((4'-(4-amino-3-methylbenzofuran-2-carboxamido)-[1,1'-biphenyl]-4-yl)sulfonyl)-L-valinate | 1208247-57-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl ((4'-(4-amino-3-methylbenzofuran-2-carboxamido)-[1,1'-biphenyl]-4-yl)sulfonyl)-L-valinate
• CAS: 1208247-57-7
• 化学式: C₂₈H₂₉N₃O₆S
• 分子量: 535.621
• InChiKey: BYNBQIWRYUVRKW-VWLOTQADSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.72
• 重原子数：
  38.0
• 可旋转键数：
  8.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  140.73
• 氢给体数：
  3.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  methyl ((4'-(4-amino-3-methylbenzofuran-2-carboxamido)-[1,1'-biphenyl]-4-yl)sulfonyl)-L-valinate 在 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 18.0h， 生成 L-2-{4'-[(4-amino-3-methylbenzofuran-2-carbonyl)amino]biphenyl-4-sulfonylamino}-3-methylbutyric acid
  参考文献：
  名称：

  3,4-Disubstituted benzofuran P1′ MMP-13 inhibitors: Optimization of selectivity and reduction of protein binding

  摘要：

  Potent 3,4-disubstituted benzofuran P1' MMP-13 inhibitors have been prepared. Selectivity over MMP-2 was achieved through a substituent at the C4 position of the benzofuran P1' moiety of the molecule. By replacing a backbone benzene with a pyridine and valine with threonine, compounds (e. g., 44) with greatly reduced plasma protein binding were also obtained. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.07.008
• 作为产物：
  描述：

  (S)-2-(4'-aminobiphenyl-4-sulfonylamino)-3-methylbutyric acid methyl ester 、 4-Amino-3-methyl-1-benzofuran-2-carboxylic acid 在 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 methyl ((4'-(4-amino-3-methylbenzofuran-2-carboxamido)-[1,1'-biphenyl]-4-yl)sulfonyl)-L-valinate
  参考文献：
  名称：

  3,4-Disubstituted benzofuran P1′ MMP-13 inhibitors: Optimization of selectivity and reduction of protein binding

  摘要：

  Potent 3,4-disubstituted benzofuran P1' MMP-13 inhibitors have been prepared. Selectivity over MMP-2 was achieved through a substituent at the C4 position of the benzofuran P1' moiety of the molecule. By replacing a backbone benzene with a pyridine and valine with threonine, compounds (e. g., 44) with greatly reduced plasma protein binding were also obtained. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.07.008